Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

EFFICACY AND SAFETY OF CREATINE SUPPLEMENTATION IN JUVENILE DERMATOMYOSITIS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CROSSOVER TRIAL

Full text
Author(s):
Show less -
Solis, Marina Yazigi [1] ; Hayashi, Ana Paula [1] ; Artioli, Guilherme Giannini [2] ; Roschel, Hamilton [2] ; Sapienza, Marcelo Tatit [1] ; Otaduy, Maria Concepcion [1] ; De Sa Pinto, Ana Lucia [1] ; Silva, Clovis Artur [1] ; Elias Sallum, Adriana Maluf [1] ; Pereira, Rosa Maria R. [1] ; Gualano, Bruno [2]
Total Authors: 11
Affiliation:
[1] Univ Sao Paulo, Sch Med, BR-01246903 Sao Paulo, SP - Brazil
[2] Univ Sao Paulo, Sch Phys Educ & Sport, BR-01246903 Sao Paulo, SP - Brazil
Total Affiliations: 2
Document type: Journal article
Source: MUSCLE & NERVE; v. 53, n. 1, p. 58-66, JAN 2016.
Web of Science Citations: 4
Abstract

Introduction: It has been suggested that creatine supplementation is safe and effective for treating idiopathic inflammatory myopathies, but no pediatric study has been conducted to date. The objective of this study was to examine the efficacy and safety of creatine supplementation in juvenile dermatomyositis (JDM) patients. Methods: In this study, JDM patients received placebo or creatine supplementation (0.1 g/kg/day) in a randomized, crossover, double-blind design. Subjects were assessed at baseline and after 12 weeks. The primary outcome was muscle function. Secondary outcomes included body composition, aerobic conditioning, health-related quality of life, and muscle phosphocreatine (PCr) content. Safety was assessed by laboratory parameters and kidney function measurements. Results: Creatine supplementation did not affect muscle function, intramuscular PCr content, or any other secondary outcome. Kidney function was not affected, and no side effects were reported. Conclusions: Twelve weeks of creatine supplementation in JDM patients were well-tolerated and free of adverse effects, but treatment did not affect muscle function, intramuscular PCr, or any other parameter. (AU)

FAPESP's process: 08/58238-4 - Autoimmunity in children: investigation of the molecular and cellular bases of early onset of autoimmunity
Grantee:Magda Maria Sales Carneiro-Sampaio
Support Opportunities: Research Projects - Thematic Grants
FAPESP's process: 10/18708-1 - Efficacy and safety of creatine supplementation in patients with juvenile onset dermatomyositis and juvenile onset systemic lupus erythematosus
Grantee:Bruno Gualano
Support Opportunities: Regular Research Grants